The FDA has rejected a radiopharmaceutical therapy from ITM Isotope Technologies Munich that was positioned to compete with Novartis’ leading treatments in the space. The agency issued a complete response letter for ITM-11, also known as 177Lu-edotreotide, saying it cannot…
